SLC5A2 and chronic kidney disease: To ascertain the effect DAPA has on renal health, the DAPA-CKD [57] and the Effects of the SGLT2 inhibitor Dapagliflozin on proteinuria in nondiabetic patients with Chronic Kidney Disease (DIAMOND) [55] trials were conducted.